Cargando…
SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021)
Esophageal cancer is an aggressive tumor, and is the sixth-leading cause of death from cancer. Incidence is rising in Spain, particularly among men. Two main pathological different subtypes have been described: squamous cell carcinoma and adenocarcinoma. Growing evidence of their epidemiology and mo...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986732/ https://www.ncbi.nlm.nih.gov/pubmed/35347573 http://dx.doi.org/10.1007/s12094-022-02801-2 |
_version_ | 1784682594477015040 |
---|---|
author | Fernández-Montes, Ana Alcaide, Julia Alsina, María Custodio, Ana Belén Franco, Lourdes Fernández Gallego Plazas, Javier Gómez-Martín, Carlos Richart, Paula Rivera, Fernando Martin-Richard, Marta |
author_facet | Fernández-Montes, Ana Alcaide, Julia Alsina, María Custodio, Ana Belén Franco, Lourdes Fernández Gallego Plazas, Javier Gómez-Martín, Carlos Richart, Paula Rivera, Fernando Martin-Richard, Marta |
author_sort | Fernández-Montes, Ana |
collection | PubMed |
description | Esophageal cancer is an aggressive tumor, and is the sixth-leading cause of death from cancer. Incidence is rising in Spain, particularly among men. Two main pathological different subtypes have been described: squamous cell carcinoma and adenocarcinoma. Growing evidence of their epidemiology and molecular differences explains their different response to novel treatments, and they are therefore likely to be treated as two separate entities in the near future. The best results are obtained with a multidisciplinary therapeutic strategy, and the introduction of immunotherapy is a promising new approach that will improve prognosis. In these guidelines, we review the evidence for the different methods of diagnosis and therapeutic strategies that form the basis of our standard of care. |
format | Online Article Text |
id | pubmed-8986732 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-89867322022-04-22 SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021) Fernández-Montes, Ana Alcaide, Julia Alsina, María Custodio, Ana Belén Franco, Lourdes Fernández Gallego Plazas, Javier Gómez-Martín, Carlos Richart, Paula Rivera, Fernando Martin-Richard, Marta Clin Transl Oncol Clinical Guides in Oncology Esophageal cancer is an aggressive tumor, and is the sixth-leading cause of death from cancer. Incidence is rising in Spain, particularly among men. Two main pathological different subtypes have been described: squamous cell carcinoma and adenocarcinoma. Growing evidence of their epidemiology and molecular differences explains their different response to novel treatments, and they are therefore likely to be treated as two separate entities in the near future. The best results are obtained with a multidisciplinary therapeutic strategy, and the introduction of immunotherapy is a promising new approach that will improve prognosis. In these guidelines, we review the evidence for the different methods of diagnosis and therapeutic strategies that form the basis of our standard of care. Springer International Publishing 2022-03-26 2022 /pmc/articles/PMC8986732/ /pubmed/35347573 http://dx.doi.org/10.1007/s12094-022-02801-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Clinical Guides in Oncology Fernández-Montes, Ana Alcaide, Julia Alsina, María Custodio, Ana Belén Franco, Lourdes Fernández Gallego Plazas, Javier Gómez-Martín, Carlos Richart, Paula Rivera, Fernando Martin-Richard, Marta SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021) |
title | SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021) |
title_full | SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021) |
title_fullStr | SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021) |
title_full_unstemmed | SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021) |
title_short | SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021) |
title_sort | seom-gemcad-ttd clinical guideline for the diagnosis and treatment of esophageal cancer (2021) |
topic | Clinical Guides in Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986732/ https://www.ncbi.nlm.nih.gov/pubmed/35347573 http://dx.doi.org/10.1007/s12094-022-02801-2 |
work_keys_str_mv | AT fernandezmontesana seomgemcadttdclinicalguidelineforthediagnosisandtreatmentofesophagealcancer2021 AT alcaidejulia seomgemcadttdclinicalguidelineforthediagnosisandtreatmentofesophagealcancer2021 AT alsinamaria seomgemcadttdclinicalguidelineforthediagnosisandtreatmentofesophagealcancer2021 AT custodioanabelen seomgemcadttdclinicalguidelineforthediagnosisandtreatmentofesophagealcancer2021 AT francolourdesfernandez seomgemcadttdclinicalguidelineforthediagnosisandtreatmentofesophagealcancer2021 AT gallegoplazasjavier seomgemcadttdclinicalguidelineforthediagnosisandtreatmentofesophagealcancer2021 AT gomezmartincarlos seomgemcadttdclinicalguidelineforthediagnosisandtreatmentofesophagealcancer2021 AT richartpaula seomgemcadttdclinicalguidelineforthediagnosisandtreatmentofesophagealcancer2021 AT riverafernando seomgemcadttdclinicalguidelineforthediagnosisandtreatmentofesophagealcancer2021 AT martinrichardmarta seomgemcadttdclinicalguidelineforthediagnosisandtreatmentofesophagealcancer2021 |